<DOC>
	<DOCNO>NCT00003309</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one drug combine chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow radiation therapy treat adult patient brain cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Adult Patients With Brain Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete partial response rate patient adult medulloblastoma , primitive neuroectodermal tumor , disseminate ependymoma treat preradiation combination chemotherapy . - Determine progression free survival overall survival adult patient treat combination chemotherapy follow craniospinal radiation . - Determine toxic effect associate treatment patient . OUTLINE : Patients receive cisplatin IV 6 hour , etoposide IV , vincristine IV 1-2 minute day 1 ; etoposide IV cyclophosphamide IV 1-2 hour day 2-3 ; filgrastim ( G-CSF ) subcutaneously ( SC ) day 4-13 ; vincristine IV 1-2 minute day 15 . Treatment repeat every 42 day 3 course absence disease progression unacceptable toxicity . Within 4-6 week last chemotherapy course , patient undergo radiotherapy 5 day week 6 7 week . Patients follow every 3 month 2 year , every 6 month 3 year , annually 5-10 year . PROJECTED ACCRUAL : A total 33 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed central nervous system cancer include : Medulloblastoma either local residual disease great 1 cm^2 MRI follow resection evidence metastasis ( M14 ) Other primitive neuroectodermal tumor Ependymoma evidence subarachnoid metastasis Must le 1 cm midline shift acute elevate intercranial pressure PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC great 4,000/mm^3 Platelet count great 125,000/mm^3 Hemoglobin great 10 g/dL No preexist hematologic condition would increase toxicity limit ability comply evaluation followup Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) SGOT le 2 time ULN Alkaline phosphatase less 2 time ULN No preexist hepatic condition would increase toxicity limit ability comply evaluation followup Renal : Creatinine great 70 mL/min No preexist renal condition would increase toxicity limit ability comply evaluation followup Pulmonary : No history significant pulmonary disease , preexist pulmonary disease , DLCO great 60 % predict No preexist pulmonary condition would increase toxicity limit ability comply evaluation followup Other : No preexist psychiatric condition would increase toxicity limit ability comply evaluation followup No prior concurrent malignancy within past 5 year except curatively treat carcinoma situ cervix basal cell squamous cell skin cancer Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : No increase dos steroids intracranial disease within 3 day registration Radiotherapy : No prior radiotherapy Surgery : 1028 day since prior surgical resection OR At least 5 day since prior biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult ependymoma</keyword>
	<keyword>adult supratentorial primitive neuroectodermal tumor ( PNET )</keyword>
</DOC>